AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00886379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mongolian milk with vitamin D
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
Study NCT00886379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT milk
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
Study NCT00886379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Substitute
Description: 710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
Study NCT00886379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seasonal D supplement
Description: Deliver dosage of 13,700 IU vitamin D over 7 days
Study NCT00886379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily D supplement
Description: Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
Study NCT03515486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post stroke mood disorders evaluation
Description: Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
Study NCT03496311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Acid - Base characterization
Description: Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
Study NCT00914849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Study NCT00914849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukopheresis
Study NCT00914849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Study NCT00441909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-781
Description: 0.1% UC-781 Vaginal Gel
Study NCT00441909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UC-781 placebo
Description: Vaginal Gel Placebo
Study NCT01312857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles
Study NCT01312857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization to No Panitumumab
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles
Study NCT02328924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LH value
Description: analyzed LH value in the the arms of the study, fixed and flexible protocols
Study NCT01995708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
Description: Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
Study NCT01995708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: No vaccines
Study NCT00770263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT00770263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT02534454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation (TDCS)
Study NCT01553084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
Study NCT02534454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (Habitrol)
Description: Administration of Nicotine Replacement Therapy Patches
Study NCT01553084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
Study NCT01553084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
Study NCT04227899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esprit BTK Device
Description: Participants will receive Esprit BTK Device
Study NCT04227899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) Device
Description: Participants will receive PTA treatment
Study NCT04021719 — intervention group
Intervention type: OTHER
Intervention: Stakeholder feedback
Description: Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
Study NCT04021719 — intervention group
Intervention type: OTHER
Intervention: Data infrastructure
Description: Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
Study NCT03119259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABC Clinical Program
Description: The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.
Study NCT03119259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC Clinical Program
Description: The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary.
Study NCT03119259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCN
Description: BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others.
Study NCT02241824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-elastic lumbar brace
Study NCT02241824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic abdominal binder
Study NCT02415608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given orally in 28-day cycles
Study NCT00635206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPap auto with Fi Flex
Description: * MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3
Study NCT00635206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP
Description: CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
Study NCT03985839 — intervention group
Intervention type: DEVICE
Intervention: MICRORAPTOR™ REGENESORB™ Suture Anchor
Description: Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
Study NCT03985839 — intervention group
Intervention type: DEVICE
Intervention: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Description: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
Study NCT03985839 — intervention group
Intervention type: DEVICE
Intervention: MICRORAPTOR™ Knotless PEEK Suture Anchor
Description: The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
Study NCT01490151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTR controller (Medtronic)
Description: Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
Study NCT00412984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
Study NCT00412984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: Oral tablets, 5.0 mg or 2.5 mg, twice daily
Study NCT04293575 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
Study NCT02854345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomoscintigraphic parathyroid imaging on a CZT camera
Study NCT03160118 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal,quadrivalent,influenza vaccine
Description: 1 dose to be administered on Day 0, the first visit
Study NCT00107198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT00107198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00107198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00107198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO
Study NCT00107198 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo IFRT
Study NCT00107198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01341834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589 and RAD001
Description: Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
Study NCT02610127 — intervention group
Intervention type: BIOLOGICAL
Intervention: OBIZUR
Description: Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
Study NCT00848926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous infusion
Study NCT02698215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 1 mg twice daily
Study NCT02698215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline plus Naltrexone
Description: Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
Study NCT03293641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate Tablets
Description: Zinc Sulfate Tablets 3 times every 7 days for 6 months.
Study NCT03293641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
Study NCT03293641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
Study NCT03656237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Training
Description: Training in a classroom setting of health care providers
Study NCT03656237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Training
Description: Training in a classroom setting of health care providers
Study NCT03656237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audits + LDHF Training
Description: Clinical audits followed by case-based low-dose high-frequency training
Study NCT01485081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Danubio paclitaxel-eluting balloon
Description: Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
Study NCT02684851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid: anti-fibrinolytic agents
Study NCT03745508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instant Coffee
Description: Instant coffee prepared at different caffeine concentrations
Study NCT03745508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Instant Coffee
Description: Instant coffee prepared at different caffeine concentrations
Study NCT03279081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cx601
Description: Cx601 eASCs intralesional injection.
Study NCT03279081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cx601 placebo-matching eASCs intralesional injection.
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Consultation
Description: Attend an enhanced consultation with decision aid
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Consultation
Description: Attend standard of care consultation
Study NCT05130580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Imaging
Description: Undergo 2D and 3D torso imaging
Study NCT05130580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Imaging
Description: Undergo 2D and 3D torso imaging
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05130580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03913533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method
Description: Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
Study NCT03913533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate assessment using Tap-based smartphone application
Description: At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
Study NCT01581801 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric Bypass
Description: Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection.
Study NCT01581801 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sleeve Gastrectomy
Description: Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
Study NCT03755934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.
Study NCT03755934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion of placebo as stated in arm description.
Study NCT01932593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of autologous bone marrow
Description: Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
Study NCT01932593 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of autologous bone marrow
Description: Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
Study NCT00307801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Study NCT00307801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day taken orally over 7 cycles of 28 pills per cycle
Study NCT03889223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical intervention with USG and comfort evaluation with NRS
Description: The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
Study NCT03889223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomical intervention with USG and comfort evaluation with NRS
Description: The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS